Mindprint implements market-leading automation solution for Ockham Oncology

Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.

Mindprint, a Toronto-based company specializing in software management solutions for the Contract Research industry, has worked onsite with Ockham to customize the new management tool, which went live in December 2013.

"Our passion is helping companies fight cancer," said Jim Baker, CEO of Ockham, which includes a global division solely focused on cancer drug trials. "We have successfully completed more than 250 oncology trials for some of the leading pharma companies.

"Because of the operational complexity in managing global trials, our conventional software tools have become cumbersome. After extensive research, we chose Mindprint as our solution."

Ockham continues to experience fast growth just two years after the successful integration of Nexus Oncology a Scotland-based oncology CRO. Mindprint, which specializes in CRO software solutions, prepared an operational plan while working closely with the Ockham team.

"We interviewed the key subject matter experts for Ockham Oncology," said Prasad A. Sristi, CEO of Mindprint."We were able to use our library of CRO solutions for demo purposes to gather quality feedback and build consensus about what Ockham needed." Both Sristi and Baker praised the thorough review of Ockham's business.

"These new tools help us serve our clients more effectively and preserve our essential focus on the clinical challenge in helping our clients in developing new cancer-fighting formulations," Baker said.

Mindprint implemented a professional services automation (PSA) tool customized for Ockham's needs. A key part of the PSA allows Ockham to measure the profitability of each clinical study - a challenging aspect of every trial due to the many data sources associated with each trial.

Sristi said the core of the technology is the patented Axpert platform developed in Bangalore by India-based Agile Labs. This tool allow the customization of enterprise management systems without extensive hard coding.

Baker praised Mindprint software's capacity to do much more for their business in addition to generating interactive reports on profitability. "The system implemented by Mindprint is exactly what we needed," Baker said. "When we began implementation, we realized that if utilized correctly Mindprint can be fundamental to our business and meet our growth demands."

The new software tools allow "much more accurate financial data and financial forecasts for our entire company," Baker said.

About Ockham
Launched in 1986, Ockham is a global oncology CRO and full-spectrum global resourcing company. Clinical expertise, therapeutic focus, and successful oncology trial outcomes have created an industry leadership position for Ockham Oncology. Ockham Source continues to achieve sustained success by offering traditional sourcing solutions as well as a growing FSP (Functional Service Provider). Ockham’s world headquarters is based in Cary, North Carolina, with the European headquarters located in Roslin, Scotland, near Edinburgh. Ockham offices are located strategically around the world to serve global customers.

About Mindprint
Mindprint Inc. specializes in serving Contract Research Organizations and pharmaceutical companies with cloud-based enterprise software solutions that provide direct business benefits such as enhanced profitability, streamlined business processes and superior customer value. Launched in 2009 and headquartered in Markham, Ontario, Mindprint has partnered with a number of leading CROs and understands the life cycle of a clinical study as well as the business challenges and system requirements unique to the life sciences industry. Mindprint's library of CRO modules, based on the Axpert enterprise resource planning platform enables rapid custom software development without expensive coding. Read more about Mindprint Inc.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...

New small molecules pave the way for treating auto…

The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to elimina...